• Prashant Shukla, G Madhava Rao, Gitu Pandey, Shweta Sharma, Naresh Mittapelly, Ranjita Shegokar, and Prabhat Ranjan Mishra.
• Pharmaceutics Division, Preclinical South PCS 002/011, CSIR - Central Drug Research Institute, Lucknow, India.
• Br. J. Pharmacol. 2014 Nov 1;171(22):5011-31.

AbstractSepsis is a clinical syndrome characterized by a multisystem response to a pathogenic assault due to underlying infection that involves a combination of interconnected biochemical, cellular and organ-organ interactive networks. After the withdrawal of recombinant human-activated protein C (rAPC), researchers and physicians have continued to search for new therapeutic approaches and targets against sepsis, effective in both hypo- and hyperinflammatory states. Currently, statins are being evaluated as a viable option in clinical trials. Many agents that have shown favourable results in experimental sepsis are not clinically effective or have not been clinically evaluated. Apart from developing new therapeutic molecules, there is great scope for for developing a variety of drug delivery strategies, such as nanoparticulate carriers and phospholipid-based systems. These nanoparticulate carriers neutralize intracorporeal LPS as well as deliver therapeutic agents to targeted tissues and subcellular locations. Here, we review and critically discuss the present status and new experimental and clinical approaches for therapeutic intervention in sepsis.© 2014 The British Pharmacological Society.

23 keywords...

hide…